Q1 2026 Financial Results

• MedLife recorded in Q1 2026 a consolidated pro-forma turnover of RON 856 million, up 10% compared to the same period of the previous year.

• The Group reports growth in most business lines, with the strongest performances being recorded by the clinics division, followed by the corporate and hospitals divisions.

• The company maintains a prudent approach for the upcoming period, while also having the investment capacity and financial flexibility to pursue potential acquisition or expansion opportunities.

• The Group is focused on growth in the areas of technology, genomics, and digitalization, accelerating the transformation of medical services through innovative solutions and projects with long-term impact.

• In the immediate future, MedLife will launch several innovative products designed to help patients monitor their health more effectively and improve their lifestyle, based on an integrated set of information ranging from genetic, biometric, and medical data to psychometric data, nutrition, and sleep patterns.

In the first three months of the year, MedLife Group recorded a pro-forma consolidated turnover of RON 856 million, up 10% compared to the same period last year, an evolution that confirms the resilience of the medical sector and MedLife's ability to adapt quickly to market changes.

The Group achieved growth on most of its business lines. The most important advances in key divisions were recorded by clinics (+14%), corporate (+11.6%) and hospitals (+11.1%). According to MedLife representatives, the corporate division not only had a good start in 2026, but continues to strengthen its market share, amid the development of new solutions adapted to the current needs of employees and the expansion of the customer portfolio. In fact, MedLife has reached the threshold of 1 million medical subscriptions in its portfolio, respectively almost half of the total market. The laboratory division also recorded an increase of more than 10% in Q1 2026 compared to the same period last year.

"The first months of the year confirmed that health remains a priority for Romanians, regardless of the economic, political or social context. At a time when many industries are experiencing slowdowns or even declines, MedLife continues to grow and perform at a sustained pace. The results reflect both the maturity of our business and the strategic investments made in recent years in infrastructure, technology and exceptional medical teams. In this context, we strongly believe that the demand for MedLife services will remain robust", said Mihai Marcu, President and CEO of MedLife Group.

As for the outlook for the rest of the year, the CEO of MedLife is confident: "We are looking at the next period with caution, but also with confidence. We have built a strong yet flexible

group to navigate difficult economic contexts and remain relevant in the long term. At the same time, we have secured the necessary resources for possible investments and we remain attentive to the opportunities that may arise in the market. We will continue to strategically analyze each development direction and act according to the context."

In addition to consolidating its financial results, MedLife continued in the first quarter of the year to accelerate its innovation projects, reaffirming its position as an innovation-oriented company based on technology and personalized medicine. Among the most important initiatives carried out in Q1 2026 is the conduct of the first genomics study in Romania, a unique research initiative in the region, through which the company contributes to democratizing access to genetic testing and personalized prevention. At the same time, the Group has maintained investments in digitalization and the development of the technological ecosystem, with a focus on MedLife application and expansion of capabilities in the area of genomics and personalized medicine - directions considered strategic for the company's development in the medium and long term.

In parallel, MedLife Group continued the organic development process by opening the first Center Dedicated to Patients with Inflammatory Bowel Diseases, in Târgul Mureș, and at the same time, completed the acquisition of MEDSTAR through the Sfânta Maria network, a transaction that strengthens the Group's presence in the Transylvania region. The company also marked a new investment of over EUR 2 million in one of the most advanced robotic neurosurgery systems in Romania, now available at MedLife Sibiu.

"Although the beginning of the year was marked by uncertainty and geopolitical risks, MedLife maintained its development path, continued to innovate and deliver value for patients, partners and shareholders. The current context forces us to remain balanced and adaptable. That is why we are preparing to operate simultaneously several scenarios and business approaches, adapted according to the evolution of the market in the next period and aligned with our strategic priorities", added Mihail Marcu.

In the coming months, the company remains focused on the operational consolidation of the business and capitalizing on development opportunities, reaffirming its commitment to patients, employees and investors to remain an innovative leader in healthcare, through investments in sustainable development and continuous adaptation to evolving market needs.

MedLife started almost three decades ago, developed healthily and became the largest provider of private medical services in Romania. The Romanian entrepreneurs, who laid the foundations of this company, invested and got involved to bring change in the Romanian health system, believed in innovation and dared to aim as high as possible, in order to offer Romanian patients quality, professionalism, care and respect for their needs.

The company operates the most extensive network of clinics, one of the largest networks of medical laboratories, general and specialized hospitals and has the largest corporate customer base for Health Prevention Packages in the country. It is also, in terms of sales, one of the largest private healthcare players in Central and Eastern Europe.

MedLife Group has a track record of success in terms of both organic growth and growth through acquisitions. Its strong and experienced management team has been able to create and manage these growth opportunities,

gaining valuable knowledge and experience that will allow it to find the best path for successful expansion continuation.

Being a Romanian company with tradition, MedLife has chosen to list on the Romanian Stock Exchange, being a model of listings on the local capital market. It has opened horizons, and through the corporate governance it has implemented, it has inspired other local companies to start on this path and help the development of Romanian capital and the economy. The shares issued by MedLife SA are admitted to trading on the regulated spot market administered by the Bucharest Stock Exchange, Premium Category, with the trading symbol "M".

During the pandemic, MedLife managed to play an essential role in society and gain a leading status in monitoring the pandemic through active involvement in the research area.

The company continues to invest in projects with an impact on the local community, in technology and infrastructure. It creates jobs and develops an ecosystem that contributes to the development and maintenance of a healthy Romania.